Metabolite-Targeted LKB1 Modulation for AMPK Kinase Activity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to regulate AMPK kinase activity for the prevention and treatment of metabolic-related diseases such as obesity, diabetes, and tumors, as the mechanism of LKB1 perception of metabolic intermediates is unclear.
Innovation Solution
Development of a novel active ingredient that targets metabolite expression levels, specifically 3-phosphoglycerate, 2-phosphoglycerate, and pyruvate, to regulate the LKB1-AMPK pathway by inhibiting the phosphorylation of the AMPK kinase α-catalytic subunit, thereby modulating kinase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LKB1 kinase or LKB1 kinase complex directly perceives intermediate products of glucose metabolism, then the activation of AMPK kinase is affected, but the specific mechanism is unclear and effective regulation methods are lacking
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that bind to LKB1 kinase or LKB1 kinase complex to modulate its activity. These compounds serve as mediators between the metabolic intermediates and the kinase, enabling controlled regulation of AMPK activation without requiring complete understanding of the natural sensing mechanism
Solution Approach 2:
The patent employs small molecule compounds that alter key parameters of LKB1 kinase function, such as binding affinity to metabolic intermediates, catalytic activity toward AMPK, or complex formation with regulatory subunits. By changing these parameters, reliable AMPK regulation is achieved while bypassing the need to fully resolve the complex natural mechanism
2Ease of operation
If metabolic intermediates (3-phosphoglycerate, 2-phosphoglycerate, pyruvate) bind to LKB1 kinase, then AMPK kinase phosphorylation is inhibited, but targeted regulation of metabolite expression levels is needed
Solution Approach 1:
The patent extracts and targets specific metabolic intermediates (3-phosphoglycerate, 2-phosphoglycerate, pyruvate) that bind to LKB1 kinase. By focusing on these specific metabolites rather than the entire metabolic network, targeted regulation becomes feasible while maintaining manageable system complexity
Solution Approach 2:
Small molecule compounds act as intermediaries that either mimic or block the binding of metabolic intermediates to LKB1 kinase. This allows targeted regulation of metabolite expression levels and LKB1 activity without requiring direct manipulation of the complex metabolic pathways themselves
3Adaptability or versatility
If upstream kinases (LKB1 and CaMKK β) phosphorylate AMPK kinase, then AMPK activation occurs, but new active ingredients for targeted regulation are urgently needed
Solution Approach 1:
The patent introduces small molecule compounds as intermediaries that can be administered as pharmaceutical compositions to regulate AMPK activation. These compounds provide flexible regulation by modulating LKB1 kinase activity or metabolite binding, while being manufacturable as standardized pharmaceutical products
Solution Approach 2:
The patent develops active ingredients that change key parameters of the LKB1-AMPK pathway, such as kinase activity levels, metabolite binding affinity, or phosphorylation rates. This provides adaptable regulation for different disease states while enabling standardized pharmaceutical manufacturing
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The active ingredient effectively downregulates metabolite production, inhibits the LKB1-AMPK pathway, and activates the AMPK pathway, providing a targeted approach for treating metabolic-related diseases.
Implementation Method 1
LKB1 and CaMKK β are known to be two important upstream kinases that phosphorylate this site
Implementation Method 2
These intermediates can directly bind to LKB1 kinase or LKB1 kinase complex and inhibit the phosphorylation of AMPK kinase α-catalytic subunit by LKB1 kinase
Data Source
Figure 1A~1G
Figure 1H~1M
AI summary
A use of an active ingredient that carries out targeted regulation of metabolite expression levels or closes off a binding site of an LKB1 protein and a metabolite for preventing and/or treating an AMPK kinase-mediated metabolic-related disease. The metabolic-related disease is selected from obesity, diabetes, tumors, inflammatory diseases, or a combination thereof.